SWM
UTHR icon

SeaCrest Wealth Management’s United Therapeutics UTHR Stock Holding History

SeaCrest Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,000
Closed -$112K – 2292
2018
Q1 		$112K Sell
1,000
-200
-17% -$25.4K 0.02% 671
2017
Q4 		$178K Buy
+1,200
New +$153K 0.03% 536

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SeaCrest Wealth Management's UTHR Position: Q2 2018 in Review

SeaCrest Wealth Management sold out of United Therapeutics (UTHR) in Q2 2018, closing a stake of 1,000 shares — an estimated $112K sold.

SeaCrest Wealth Management first reported a position in UTHR in Q4 2017 and held it in 2 quarters. The position peaked at $178K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q2 2018.

  • SeaCrest Wealth Management reported no remaining United Therapeutics position as of Q2 2018 after selling out during the quarter.
  • SeaCrest Wealth Management sold 1,000 United Therapeutics shares in Q2 2018, an estimated $112K.
  • SeaCrest Wealth Management first reported a position in United Therapeutics in Q4 2017 and held it in 2 quarters.
  • SeaCrest Wealth Management's United Therapeutics position peaked at $178K in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2018.

Based on SeaCrest Wealth Management's 13F filing for Q2 2018, filed 3 Aug 2018.